The word oral, both in its Latin root and in common usage, essentially describes the mouth. The mouth is a portal of entry as well as a mirror that reflects a wealth of information that can be derived from oral fluids and tissues. The recent progress of the human and microbial genomes provides unprecedented opportunities to not only understand the molecular basis of oral diseases, but to design and fabricate new generations of diagnostics, therapeutics and biomaterials. In parallel developments, remarkable progress is being made to understand human as well as oral microbial (viral, bacterial and yeast) genetic variations including their respective responses to drug therapies. Oral infections and systemic diseases are a global health challenge. In tandem, drug discovery is focusing on the identification and validation of pharmaceutical targets in the molecular pathways or circuits embedded within our growing knowledge base of oral microbial and human functional genomics. The management of chronic oral and craniofacial pain present significant opportunities for pharmacogenomics. Biomimeticbased innovations leading to new biomaterials for the replacement of tissues and organs are also being advanced and evaluated as a direct consequence of the nexus between pharmacogenomics, biotechnology, informatics and clinical health care.
PROGRESS AND OPPORTUNITIES IN ORAL HEALTH
The recent first-time ever Surgeon General's Report Oral Health in America provides a comprehensive and evidence-based assessment of oral health and oral health care in America.
1 Significant progress has been made in reducing the extent and severity of common oral diseases in most people through a variety of preventive measures adopted by nations, communities, individuals and oral health professionals. 1 However, not everyone is experiencing the same degree of improvement or resistance to oral diseases and disorders.
The word oral, both in its Latin root and in common usage, essentially describes the mouth. The mouth is a portal of entry as well as a mirror that reflects a wealth of information that can be derived from oral fluids and tissues. The mouth includes not only the teeth and the gums (gingiva) and their supporting connective tissues, ligaments, and bone, but also the hard and soft palate, the mucosal lining of the mouth and throat, the tongue, the lips, the salivary glands, the oral fluid saliva, the muscles of mastication, and the upper (maxillary) and lower (mandibular) jaws, which are connected to the skull by the two synovial temporomandibular joints. Equally significant are the paired branches of the nervous, the immune and vascular systems that animate, protect and nourish the oral tissues, as well as provide connectivity with the brain and the rest of the body. The term craniofacial-oral-dental complex captures these anatomical and physiological relationships.
As the gateway to the body, a constant barrage of invaders-viruses, bacteria, parasites, and fungi, challenges the mouth. Therefore, transmissible infectious diseases, notably dental caries and periodontal disease, predominate among the ills that can compromise oral health. Dental caries is the most common chronic disease of childhood.
1 Among 5-to 17-year-olds, dental caries is more than five times as common as asthma, and seven times more common than hay fever. 1 The word caries derives from the Latin for rotten. Today we appreciate that dental caries is a transmissible infectious disease and that the bacterial pathogens are transmitted from caregiver to infant during early childhood. The bacteria colonizing the mouth are known as the oral flora.
These microbes form a complex dental plaque of biofilms that adheres to tooth surfaces. 2 Within these biofilms, mutans streptococci and several other bacteria ferment sugars and other carbohydrates to form lactic and other acids. Repeated cycles of acid generation can result in the microscopic dissolution of minerals in tooth enamel with the presentation of an opaque white or brown spot under the enamel surface. The initiation and progression of this chronic infectious disease is modulated by genetic variations of the microbial quorum sensing, colonization and acid production within the biofilms, the host genetic variations in enamel matrix composition and structure, the environment such as the presence of fluoride in drinking water, and caregiver as well as infant/toddler/child behavioral factors (frequency and duration of consumption and composition of food and drink choices along with personal oral hygiene). Mechanical tooth brushing, chemicals as well as immunological (ie monoclonal antibodies as 'plantibodies' for passive immunization against microbial antigens related to colonization) methods are used to inhibit or reduce microbial colon- ization on tooth surfaces. The advances from human and microbial genomics provide many opportunities for targeted therapies such as vaccine developments for children at risk for dental caries. (Figure 1 ).
Chronic oral infections are also associated with heart and lung diseases, cerebrovascular stroke, and low-birthweight, premature babies.
1-2 In 2001, there were 100 million people in America, approximately 40% of the population, who presented chronic diseases and disorders. 1 One of the major chronic infections is Periodontitis. The microbes associated with this chronic and destructive disease are Porphyromonas gingivalis, Prevotella intermedia, Bacterioides forsythus, Treponema denticola, and Actinobacillus actinomycetemcomitans. 2 Additional evidence implicates several viral pathogens. The virulence of these pathogens includes their role in colonization in subgingival biofilms, synthesis and secretion of cytokines that can directly injure adjacent tissues, and their capacity to invoke inflammatory responses. 2 Most prominent in periodontal diseases are prostaglandin E2 and a number of cytokines such as interleukins, tumor necrosis factor, and interferon. Completion of the human genome, microbial genomes and functional genomic studies will reveal the hereditability of susceptiwww.nature.com/tpj bility to a variety of infectious diseases, critical cellular pathways associated with the initiation and progression of disease, and may also provide candidate targets for combined drug therapies.
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Candida albicans is the most common fungal pathogen isolated from the oral cavity. Deficiencies in the immune and endocrine systems in children as well as adults, as well as cancer chemotherapy invoke oral candidiasis. Chronic hyperplastic as well as pseudomembranous oral candidiasis may reveal immunodeficiency and serve as a sign of HIV infection. The spread of candidiasis to the esophagus or lungs, especially in immunodeficient individuals, can often be life threatening. The near completion of the Candida albicans genome will soon accelerate the identification of innovative antifungal therapies.
Injuries take their toll as well, with the craniofacial-oral-dental complex particularly vulnerable to sports injuries, automobile accidents, and domestic violence such as child and spousal abuse. Less common but very serious are oral and pharyngeal cancers (essentially squamous cell carcinoma), with a 5-year survival rate of just over 50%; one American dies every hour of oral cancer. 1 Oral cancer is the sixth most common cancer in US males, and takes a disproportionate toll on African-American males. 1, [8] [9] [10] [11] Multiple and sequential mutations are associated with oral, pharyngeal and tonsillar squamous cell carcinoma. 11 Oncogenes, proto-oncogenes, and tumor suppressor genes are implicated in oral cancers. 11 Human and viral genome completion and a variety of functional genomic studies suggest several gene-gene and gene-environment (sunlight, alcohol and tobacco) interactions that are particularly informative. For example, the p53 concentrations are very low in normal squamous epithelial cells due to continuous degradation by the enzyme MDM2. Environmental insults such as alcohol, ultraviolet light, and/or tobacco products presumably increase DNA 'damage,' reduce MDM2, increase p53, and thereby activate clusters of genes associated with cell growth, and/or cell death (apoptosis). Qualitative as well as quantitative changes are being discovered through DNA microarray techniques. 11 Birth defects frequently affect the craniofacial-oral-dental complex. These developmental malformations appear most commonly as isolated cases of cleft lip with or without cleft palate; facial clefting and/or other craniofacial defects can also be part of complex hereditary diseases or craniofacial syndromes. At this time, hundreds of genetic mutations have been identified that result in facial developmental defects and dental extracellular matrix tissue defects such as enamel (Amelogenesis imperfecta), dentin (Dentinogenesis imperfecta), bone (osteogenesis imperfecta), and cartilage (chondrodysplasia). Mutations in the cathepsin C gene are linked to the Papillon-Lefevre syndrome that presents an extreme example of destructive periodontal disease in children as well as in adults.
Additionally, acute and chronic pain can affect the craniofacial-oral-dental complex, particularly in and around the temporomandibular joints, and accounts for a disproportionate amount of all types of pain that cause individuals to seek health care. Recent scientific evidence indicates striking genetic variations in receptors as well as pain perceptions between genders.
Increasing evidence also suggests striking variance within genders, for example, the variance observed in the individual patient absorption and metabolism of a variety of analgesic therapeutics. The management of chronic pain is an ideal problem for pharmacogenomics that could result in individualized and optimal clinical efficacy. Accessing genetic variation using single nucleotide polymorphisms (SNPs) will become very useful to dissect variations in drug metabolism. 5, 7 Many systemic chronic diseases and disorders such as diabetes, arthritis, osteoporosis, chronic fatigue syndrome, fibromyalgia, Sjogren's syndrome, and AIDS, as well as therapies for systemic diseases, can directly or indirectly compromise oral tissues.
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Using SNP-genotyping or other high 
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The Pharmacogenomics Journal throughput technologies, the multiple genes in complex human diseases will be identified and the time of expression and mechanisms of action will be ascertained. 6, 7 These advances should lead to interventions for health promotion, risk assessment and disease prevention as well as therapeutics for treatment.
These diseases and disorders of the craniofacial-oral-dental complex at this time in human history are coupled with the 'golden age of molecular oral health.' The progress from the human genome, microbial genomes, proteomics, bioinformatics and biotechnology herald the promises of gene-based diagnostics, gene-targeted therapeutics, and biomimetics with the design and fabrication of innovative organs, tissues and biomaterials.
Risk assessment for disease is increasingly being based upon subtle human and microbial genetic variances detected by SNPs. 7, 11 These multiple genetic variables are enhancing our collective knowledge of susceptibility and/or resistance to disease. A number of candidate genes have been identified as putative risk factors for dental caries and periodontal diseases. [8] [9] [10] [11] [12] Gene therapy is being applied to treat oral and pharyngeal cancers, xerostomia or 'dry mouth,' and to deliver targeted therapy for oral infections and systemic diseases.
14 Gene-mediated therapeutics are being developed to enhance soft and hard tissue healing, repair and regeneration such as bone morphogenetic proteins (BMPs), and platelet-derived growth factors (PDGFs). [10] [11] [12] An important issue to consider is the increasing number of polymorphisms in G-pro-tein-coupled receptors, which can alter drug affinity and/or bioactivity. For example, patients with a mutation in the gene encoding for the enzyme CYP2D6 will show little or no analgesic effect from codeine. Codeine is metabolized to its active metabolite, morphine, by the enzyme CYP2D6. 15 A number of highly specific drugs are being discovered for a variety of oral diseases and disorders such as oral candidiasis, recurrent aphthous ulcers, herpetic lesions, HHV8 and Kaposi Sarcoma, and chronic facial pain associated with trigeminal neuralgia and Bell's palsy (Figure 2) .
The opportunities for pharmacogenomics to impact the study of differential gene expression applied to drug discovery and optimization are remarkable. These advances will likely include the discovery of new drug targets, the discovery of new disease and disorder mechanism(s) of the drug, the confirmation of expected action(s) of mechanism of a drug, and the optimal clinical efficacy of the drug or therapeutic for oral health care.
CONVERGENCE OF CLINICAL ORAL HEALTH CARE, INFORMATICS, AND BIOTECHNOLOGY
The scientific and technological bases of dentistry, medicine, nursing, and pharmacy are expanding rapidly in parallel with changing demographics of industrial nations, the public's expectations for an enhanced quality of life, and changes in the management and financing of health care. Health professional schools, often organized around academic health science centers, are responding to these challenges and opportunities. 10, 11 www.nature.com/tpj Public and private sector funding for clinical research will continue to enhance multicenter, prospective and randomized clinical trials, along with behavioral interventions to advance health promotion, risk assessment, and disease prevention. Students and practitioners alike will need to be prepared to adopt evidence-based health care.
Today and tomorrow, clinicians must be well educated in epidemiology, biometry, bioinformatics, molecular medicine and dentistry, bioengineering, and much more. In addition, they will be challenged to adopt and implement new preventive strategies as well as molecular-based diagnostics and therapeutics. Clinical scientific evidence in the new millennium will continue to rapidly expand and shape the future of health care. Of course, with rapid progress and scientific discoveries will come more questions and more opportunities for research. We are living at a time in human history when the clinical sciences, information and information sciences, and biotechnology converge. 
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